Dell'Osso BM

Department of Mental Health and Addiction, Azienda Socio Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco, Milan, Italy.

6 papers

ArticlePsilocybin

Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review.

Civardi SC, Besana F, Durbano F +4

Europe PMC2026
ArticleKetamine

Functional outcomes with esketamine in treatment-resistant depression: A 6-month multicenter real-world study.

Guglielmo R, Olivola M, Inuggi A +9

Europe PMC2026
ArticleKetamine

Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group.

d'Andrea G, Cavallotto C, Pettorruso M +25

Europe PMC2025
ArticleKetamine

Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group.

Rosso G, d'Andrea G, Barlati S +15

Europe PMC2025
ArticleKetamine

Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study.

d'Andrea G, Miuli A, Pettorruso M +12

Europe PMC2024
ArticleKetamine

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.

d'Andrea G, Pettorruso M, Di Lorenzo G +16

Europe PMC2024